Grade 3/4 adverse events occurred almost five times as often in the combination arm, he added, and combining sasanlimab to BCG will significantly increase the cost of treatment. "I think it is ...

That’s why you should regularly revise and update your BCG matrix as market conditions change. For instance, a product that was a Question Mark could quickly turn into a Dog, so you should be ...

Among 110 patients with BCG-unresponsive CIS treated with cretostimogene grenadenorepvec, the complete response (CR) rate at any time was 75.5%, and the 24-month CR rate was 33.7%, Mark Tyson ...

The results are impressive, even with such a long follow-up period and as few as 45 patients in the mitomycin C arm and 44 patients in the BCG arm. Furthermore, this advantage was sustained over ...

Follow-up concluded in July 2018. In the mBCG arm, 2/25 (8% of randomly assigned) participants did not commence treatment and 23/25 (92.0% of randomly assigned) started BCG, all within 4 weeks of ...

At this meeting all key decision makers were specifically asked and unanimously confirmed that ImmunityBio should submit the sBLA as soon as possible based on the data in the single-arm trial.